Cardiome Pharma Corp has entered into a US$68-million strategic partnership agreement with Fujisawa Healthcare Inc, the US subsidiary of Fujisawa Pharmaceutical Co Ltd of Japan. The deal pivots on co-development of RSD1235, Cardiome’s intravenous antiarrhythmic agent. Fujisawa will pay Cardiome $10 million up front, $54 million in milestone payments and $4 million in an equity placement with Fujisawa Healthcare. Fujisawa gains exclusive commercialization rights to RSD1235 to treat atrial fibrillation and atrial flutter. It will cover 75% of future clinical development costs while Cardiome will cover 25%....
Other stories mentioning these organizations, people and topics
| Organizations: | Cardiome Pharma Corp, Fujisawa Healthcare Inc, and Fujisawa Pharmaceutical Co Ltd of Japan |
Other News
Events For Leaders in
Science, Tech, Innovation, and Policy
Discuss and learn from those in the know at our virtual and in-person events.
See Upcoming Events
You have 1 free article remaining.
Don't miss out - start your free trial today.
Start your FREE trial Already a member? Log in
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.